• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by BeOne Medicines Ltd.

    7/9/25 4:15:42 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001042047
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    BEONE MEDICINES LTD.
    SEC File Number
    001-37686
    Address of Issuer
    Aeschengraben 27, 21st Floor
    Basel
    SWITZERLAND
    4051
    Phone
    41-616851900
    Name of Person for Whose Account the Securities are To Be Sold
    JOHN V OYLER
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director
    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    ADS
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    278026796754.945696473907/09/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    ADS06/30/2021Restricted Stock UnitsIssuerCheckbox not checked2780206/30/2021N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    10b5-1 Sales for PAN-OYLER FOUNDATION
    Aeschengraben 27, 21st Floor
    Basel � V8 � 4051
    ADS07/08/20251661406520.95
    JOHN OYLER
    Aeschengraben 27, 21st Floor
    Basel � V8 � 4051
    Common06/23/20253174830359.98
    JOHN OYLER
    Aeschengraben 27, 21st Floor
    Basel � V8 � 4051
    Common06/17/20251460374473.21
    JOHN OYLER
    Aeschengraben 27, 21st Floor
    Basel � V8 � 4051
    Common06/16/20253680979046.34
    JOHN OYLER
    Aeschengraben 27, 21st Floor
    Basel � V8 � 4051
    Common06/06/202551271295996.91

    144: Remarks and Signature

    Remarks
    The securities to be sold were acquired upon the vesting of restricted stock units during the period of 06/30/2021 through 06/22/2025.
    Date of Notice
    07/09/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ John V Oyler

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ONC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    SEC Filings

    View All

    SEC Form 10-Q filed by BeOne Medicines Ltd.

    10-Q - BeOne Medicines Ltd. (0001651308) (Filer)

    8/6/25 6:05:46 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    8/6/25 6:02:43 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    7/9/25 4:15:42 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

    Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit

    8/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia

    Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. "This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced inte

    7/31/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

    Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological response If approved, the expanded label builds on TEVIMBRA's momentum in lung cancer with EU approvals already in NSCLC and SCLC indications across both first- and second-line settings BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with platinum-containi

    7/28/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Wu Xiaobin exercised 89,794 units of American Depositary Shares at a strike of $160.78 and sold $27,347,635 worth of American Depositary Shares (89,794 units at $304.56) (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    8/15/25 4:40:17 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, General Counsel Lee Chan Henry sold $3,308,877 worth of American Depositary Shares (11,013 units at $300.45) and exercised 8,230 units of American Depositary Shares at a strike of $177.90, closing all direct ownership in the company (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    8/15/25 4:38:46 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Rosenberg Aaron sold $345,659 worth of American Depositary Shares (1,190 units at $290.47), closing all direct ownership in the company (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    8/5/25 5:16:07 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on BeiGene with a new price target

    RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

    4/7/25 8:43:36 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeiGene upgraded by BofA Securities with a new price target

    BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously

    3/3/25 7:35:01 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Financials

    Live finance-specific insights

    View All

    BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

    Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit

    8/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeiGene Announces First Quarter 2025 Financial Results and Business Updates

    First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

    5/7/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeiGene to Announce First Quarter 2025 Financial Results on May 7

    BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

    4/17/25 6:01:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care